Encompass Health (NYSE:EHC – Get Rating) updated its FY 2022 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $3.76-$4.05 for the period, compared to the consensus estimate of $4.12. The company issued revenue guidance of $5.33 billion-$5.42 billion, compared to the consensus revenue estimate of $5.46 billion.
EHC has been the subject of several recent research reports. Royal Bank of Canada decreased their price target on Encompass Health from $85.00 to $82.00 in a report on Wednesday, June 8th. Credit Suisse Group cut their price target on Encompass Health from $83.00 to $82.00 and set an outperform rating for the company in a research note on Friday. TheStreet upgraded Encompass Health from a c+ rating to a b- rating in a research note on Tuesday, March 15th. Truist Financial raised their price target on Encompass Health from $78.00 to $85.00 in a report on Thursday, April 7th. Finally, StockNews.com cut Encompass Health from a buy rating to a hold rating in a report on Friday. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of Buy and an average target price of $82.75.
NYSE:EHC opened at $56.15 on Tuesday. The stock has a 50-day simple moving average of $66.52 and a two-hundred day simple moving average of $65.68. Encompass Health has a 52-week low of $55.69 and a 52-week high of $85.75. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.26. The firm has a market capitalization of $5.60 billion, a PE ratio of 14.36, a P/E/G ratio of 1.93 and a beta of 0.96.
Encompass Health (NYSE:EHC – Get Rating) last issued its quarterly earnings data on Wednesday, April 27th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Encompass Health had a return on equity of 17.99% and a net margin of 7.51%. The business had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the prior year, the business posted $1.05 earnings per share. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. Equities analysts forecast that Encompass Health will post 4.09 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 20th. Shareholders of record on Wednesday, July 13th will be given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 1.99%. The ex-dividend date of this dividend is Tuesday, July 12th. Encompass Health’s dividend payout ratio is presently 28.64%.
In other Encompass Health news, Director Kevin J. O’connor acquired 1,000 shares of the company’s stock in a transaction dated Friday, May 6th. The shares were acquired at an average cost of $66.48 per share, with a total value of $66,480.00. Following the acquisition, the director now directly owns 3,436 shares of the company’s stock, valued at $228,425.28. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.70% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Worth Asset Management LLC purchased a new stake in shares of Encompass Health in the first quarter valued at about $35,000. EverSource Wealth Advisors LLC purchased a new position in shares of Encompass Health in the fourth quarter valued at approximately $78,000. Covestor Ltd boosted its stake in shares of Encompass Health by 157.1% in the first quarter. Covestor Ltd now owns 1,481 shares of the company’s stock valued at $105,000 after purchasing an additional 905 shares during the period. Canada Pension Plan Investment Board acquired a new stake in Encompass Health in the first quarter valued at approximately $178,000. Finally, Virtu Financial LLC acquired a new stake in Encompass Health in the fourth quarter valued at approximately $297,000. Institutional investors and hedge funds own 91.70% of the company’s stock.
About Encompass Health (Get Rating)
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Featured Articles
Receive News & Ratings for Encompass Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Encompass Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
